Singulair - Biotech, Pharma and Life Science Channel
Singulair, the brand name for montelukast sodium, is produced by Merck & Co., Inc. Its annual sales in 2009 were $3m, ranking it 7th in the world.
Singulair acts by blocking leukotrienes, to reduce to reaction of the body to allergic substances. It is used in the treatment of asthma (to prevent attacks) and the relive the symptoms of allergies (such as hayfever and animals). It can be used in pediatric cases.
Source; Adapted from BioPortfolio.com and Singulair.com
Add the Singulair News Channel to your RSS reader;
Follow the Singulair Twitter feed;
News Articles
Technical Review: New Releases from Drug Maker Majors Cushion Against Patent Cliff Effects
LONDON, January 16, 2013 /PRNewswire/ -- All companies mentioned in the release below have received technical review as of the close of yesterday's session. These reports are available for free at ht...
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck/Kyorin’s Singulair is a dominant player a...
NEW YORK, Nov. 21, 2012 /PRNewswire/ -- As in the previous quarter, proton-pump inhibitors, antipsychotics and statins remain in the top-selling therapeutic categories. Merck's asthma and allergy...
Dr. Reddy’s Announces the Launch of Montelukast Sodium Oral Granules
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair® (montelukast sodium) o...
HealthWarehouse.com Reports 38% Year-Over-Year Revenue Growth in the First Quarter 2012
CINCINNATI, Sept. 5, 2012 /PRNewswire/ -- HealthWarehouse.com, Inc. (OTC: HEWA) a leading VIPPS accredited retail mail-order pharmacy, today announced its financial results for the first quarter...
Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
NEW YORK, Aug. 21, 2012 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2012 U.S. prescription sales data for the top 100 drugs. Proton-pump i...
Mylan Launches Generic Version of Singulair® Tablets and Singulair® Chewable Tablets
PITTSBURGH, Aug. 7, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration...
Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequiva...
Qualitest Launches Generic Singulair®
HUNTSVILLE, Ala., Aug. 6, 2012 /PRNewswire/ -- Qualitest Pharmaceuticals today confirmed that it has launched a generic version of Singulair (montelukast sodium) Tablets and Chewable Tablets,...
FDA approves first generic versions of Singulair to treat asthma, allergies
The U.S. Food and Drug Administration today approved the first generic versions of Singulair (montelukast sodium) for use in adults and children to control asthma symptoms and to help relieve symptoms...
Events
None
Companies
None
Clinical Trials
Transporter Mediated Uptake of Montelukast
Leukotriene receptor antagonists (LTRAs) are frequently prescribed to reduce the symptoms associated with asthma. Singulair, manufactured by Merck, is a popular LTRA, however its effectiv...
Trial of Montelukast in Eosinophilic Esophagitis
Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE. Also evaluate tolerance and safety of oral monte...
This randomized, double-blind, placebo-controlled trial assessed the efficacy of montelukast in the treatment of adults ≥50 years of age with persistent asthma and/or COPD. Primary outc...
Montelukast to Treat Bronchiolitis Obliterans
Background: Bronchiolitis obliterans is a form of chronic graft-versus-host disease (GVHD) that sometimes develops after stem cell transplantation (SCT) or bone marrow transplantation...
Montelukast in Very Low Birthweight Infants
The purpose of this study is to determine the pharmacokinetics (PK) of montelukast (Singulair) in very low birth weight (VLBW) infants at risk for developing bronchopulmonary dysplasia (th...
SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen
The purpose of this study is to assess the treatment effect of montelukast 10mg on the primary endpoint of Asthma Control Questionnaire(ACQ), over a 8-week period, in persistent asthma pat...
The four respiratory drugs being researched in this study have been approved by the US Food and Drug Administration (FDA) and are currently available by prescription at your drug store. O...
Quality of Life in Asthma and Rhinitis Allergic With Singulair
Allow physicians not familiar with anti-leukotriene based therapy to test it
Study With GW274150 In Patients With Mild Asthma
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response. Th...
The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment accor...
PubMed Articles
Anti-cholinergic effect of singulair on isolated rat's tracheal smooth muscle.
Singulair (Montelukast) is a potent and selective leukotriene D(4) receptor antagonist, often used in treating inflammatory conditions of the respiratory system such as allergic rhinitis and asthma. H...
Videos
Parents Fear Singulair Is a Prescription For Disaster
It's a drug that's helping millions of children with asthma and allergies breathe easier but some families believe Singulair can lead to depression and even ...
